Quality of life in childhood onset growth hormone-deficient patients in the transition phase from childhood to adulthood.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.

Quality of life (QoL) has not been specifically assessed in GH-deficient (GHD) transition patients.

Who Took Part

PubMed indexes the participants as teenagers and adults, both men and women.

The researchers assessed QoL at baseline and after 1 and 2 yr of GH treatment in severely GHD patients, using an adult GHD-specific questionnaire, QLS(M)-H.

How the Study Was Run

The design is described as randomized.

Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

What Was Measured

Quality of life (QoL) has not been specifically assessed in GH-deficient (GHD) transition patients.

Topics PubMed links to this paper include Age of Onset, Growth Disorders, Human Growth Hormone, Quality of Life, Stress, Psychological and Surveys and Questionnaires.

What This Means in Plain Language

The paper is a randomized study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2005 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.